TY - JOUR
T1 - Strategies for replacing myocytes with induced pluripotent stem in clinical protocols
AU - Hattori, Fumiyuki
AU - Fukuda, Keiichi
N1 - Funding Information:
We thank the Special Coordination Funds for Promoting Science and Technology in the Japanese Ministry of Education, Culture, Sports, Science, and Technology and KAKENHI.
PY - 2012/7
Y1 - 2012/7
N2 - Induced pluripotent stem (iPS) cells can be established via forced epigenetic reprogramming of various somatic cells and selection based on given criteria. Human iPS cells are preferred for clinical applications because they present fewer ethical concerns than embryonic stem cells. However, technical issues of stability and safety must be fully validated before clinical use. Moreover, heart regenerative therapies would require approximately 109 cardiomyocytes per person, necessitating the following technical considerations: (1) genetically and epigenetically stable scaling up of the iPS cells, (2) efficient and reproducible differentiation, and (3) highly reliable cell purification. Furthermore, (4) strategies for efficient iPS transplantation, rapid maturation, and functional integration of grafted cardiomyocytes into the host myocardium are critical unmet technologies. Herein, we discuss current progress and unmet problems for the realization of heart regenerative therapy.
AB - Induced pluripotent stem (iPS) cells can be established via forced epigenetic reprogramming of various somatic cells and selection based on given criteria. Human iPS cells are preferred for clinical applications because they present fewer ethical concerns than embryonic stem cells. However, technical issues of stability and safety must be fully validated before clinical use. Moreover, heart regenerative therapies would require approximately 109 cardiomyocytes per person, necessitating the following technical considerations: (1) genetically and epigenetically stable scaling up of the iPS cells, (2) efficient and reproducible differentiation, and (3) highly reliable cell purification. Furthermore, (4) strategies for efficient iPS transplantation, rapid maturation, and functional integration of grafted cardiomyocytes into the host myocardium are critical unmet technologies. Herein, we discuss current progress and unmet problems for the realization of heart regenerative therapy.
UR - http://www.scopus.com/inward/record.url?scp=84863103779&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863103779&partnerID=8YFLogxK
U2 - 10.1016/j.trre.2011.09.003
DO - 10.1016/j.trre.2011.09.003
M3 - Review article
C2 - 22172453
AN - SCOPUS:84863103779
SN - 0955-470X
VL - 26
SP - 223
EP - 232
JO - Transplantation Reviews
JF - Transplantation Reviews
IS - 3
ER -